B

이오플로우

294090KOSDAQ의료용 기기 제조업

56.9 / 100

Reference Date: 2026-07-24

Financial Score20.0 / 40
News Sentiment16.9 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

EoFlow is a medical device company established in 2011, specializing in wearable insulin pumps using electroosmotic pump technology. It launched the disposable wearable insulin pump EOPatch in 2021, which offers superior convenience, waterproofing, and longer replacement intervals compared to existing products, securing a competitive edge in the diabetes medical device market. The company expanded into European markets in 2022 and is exploring diverse fields such as obesity and NASH treatments through non-insulin pump business. However, its non-insulin business has been halted due to a lawsuit with Insulet.

Number of Employees

51people

Average Salary

55.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 20.044.0Point
PBR
Industry Average 1.143.5Point
ROE
Industry Average 8.003.5Point
Debt Ratio
-5.38Industry Average 11.658.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼25.4% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -140.2% (declining, 2yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 1,490Won52-week high 1,49052-week low 1,490
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral기타시장안내 (개선계획서 제출)2026-07-22
  • Neutral기타시장안내 (상장적격성 실질심사 대상 결정)2026-06-30
  • Neutral주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)2026-06-30